Trending Topic

20 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as T2D, using non-invasive biomarkers. This article explores the rationale to screen for advanced fibrosis in people with risk […]

Andrea R Genazzani, WCO IOF-ESCEO 2022: Hormone Replacement Therapy for Bone Loss Prevention Post Menopause (Part 2)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 5th 2022

It was a pleasure to talk with Dr. Andrea R Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to find out when, in whom and for how long hormone replacement therapy should be administered for bone loss prevention post-menopause.

Hormone Replacement Therapy in post-menopause for bone loss prevention: when, how and for how long‘ was presented at WCO IOF-ESCEO 2022, 24-26 March, 2022

Questions

  1. When and in whom should HRT be considered for bone loss prevention? (1:16)
  2. How can HRT be administered? (3:45)
  3. For how long should HRT be administered? (5:59)

Disclosures: Andrea R Genazzani has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the WCO IOF-ESCEO annual meeting 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup